Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tyligand Bioscience (Shanghai) Limited is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and is being handled within 1 distinct art unit. This singular focus indicates that the company's current patent activity is concentrated on a specific pharmaceutical technology. By operating in 1 distinct art unit, the company only needs to navigate the specific examination criteria of a single administrative group.
Abigail Louise Vanhorn is the busiest examiner for this portfolio, currently overseeing 1 pending office action. This examiner is responsible for the entirety of the company's pending office actions. With only 1 distinct examiner involved, the company's prosecution strategy is highly centralized. There are no other examiners or art units available in the data to provide a comparative baseline for performance or expectations. As a result, the success of the company's current efforts in the Biotechnology & Pharmaceuticals field is entirely dependent on the interaction with this single official.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VANHORN, ABIGAIL LOUISE | 1 | 46.8% | +22.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18032663 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | VANHORN, ABIGAIL LOUISE | 22d |
| Art Unit | Apps |
|---|---|
| 1636 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18032663 | MULTIFUNCTIONAL CYCLIC DINUCLEOTIDE AND USE THEREOF | VANHORN, ABIGAIL LOUISE | 1636 | §103 | Non-Final OA | 22d | Pending | Apr 19, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTyligand Bioscience (Shanghai) Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Abigail Louise Vanhorn has the most, with 1 of Tyligand Bioscience (Shanghai) Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
